Relieved of ‘high-risk’ marker, New Horizon Health aims to break even next year
Encouraged by its fast-growing revenue last year, the cancer screening device maker believes its losses may end in 2023 Key Takeaways: New Horizon Health is expected to attract more investors…
Genecast Hopes for High IPO Valuation Despite Red Ink, Regulatory Risk
The maker of cancer diagnostics and testing products has made a second filing for a Hong Kong IPO, even as its industry faces regulatory risk due to the newness of…
Mega Genomics Eyes Hong Kong IPO To Ride Growing Popularity of Genetic Testing
The genetic testing company is looking to raise up to $33 million in a Hong Kong IPO as its services become popular in China Key Takeaways: Mega Genomics is looking…
FAST NEWS: Genetron’s Losses Grow as Covid Restrictions Hurt Business
The latest: Cancer-screening device maker Genetron Holdings Ltd. (GTH.US) said on Thursday its revenue grew 9.6% year-on-year in the fourth quarter to 146.9 million yuan ($23 million). Its loss for…
Recent Articles
RELATED ARTICLES
-
Horizon’s lead grows in smart driving race with new product rollouts
9660.HK - Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
BRIEF: New Horizon Health announces chairman’s departure
6606.HK
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
-
iMotion Automotive rides DeepSeek fever to new fundraising
1274.HK
